Save 20% on Mavyret - called Maviret internationally
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe
AbbVie S.r.l.
S.R. 148 Pontina km 52 SNC
04011 Campoverde di Aprilia (LT)
Italy
Information about Mavyret (Glecaprevir/Pibrentasvir)
Mavyret is a fixed-dose combination medication that includes glecaprevir and pibrentasvir. It is used for the treatment of chronic hepatitis C virus (HCV) infection. This combination therapy targets multiple steps in the viral life cycle, effectively eliminating the virus.
Product Highlights
- Indicated for the treatment of adults and pediatric patients aged 3 years and older with chronic HCV infection, including those with compensated cirrhosis.
Key Ingredient
Key Benefits
- Achieves high cure rates in patients with various HCV genotypes.
- Fewer drug interactions compared to other HCV treatments, making it easier for patients on multiple medications.
- Typically well-tolerated, exhibiting a favorable side effect profile.
Direction of Use
- Take Mavyret exactly as prescribed by your healthcare provider, typically once daily with food.
- For the best outcomes, take the medication at the same time each day.
- Regular follow-up appointments for monitoring treatment response and liver function tests are recommended.
Safety Concerns
- Frequent side effects may include headache, fatigue, nausea, and diarrhea.
- Liver function should be regularly monitored, particularly in patients with existing liver conditions.
- Caution is warranted in patients with a history of hepatitis B virus infection.
Avoid Mavyret (Glecaprevir/Pibrentasvir) If
- History of hypersensitivity to glecaprevir, pibrentasvir, or any components of the formulation.
- Not recommended for individuals with decompensated cirrhosis or severe hepatic impairment.
- Avoid in patients taking medications that are contraindicated due to potential interactions, such as some anticonvulsants and herbal supplements like St. John's Wort.
